Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215715 · ClinicalTrials.gov registry record
US Benchmarking Clinical Study
A clinical trial of Cardiac Amyloidosis and Left Ventricular Hypertrophy, sponsored by eMyosound SAS.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT07215715: Recruiting study of Cardiac Amyloidosis and Left Ventricular Hypertrophy, sponsored by eMyosound SAS.
NCT07215715 is a study of Cardiac Amyloidosis and Left Ventricular Hypertrophy that is actively recruiting participants, run by eMyosound SAS. The registered enrollment target is 150 participants, below the 936-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215715, a study of Cardiac Amyloidosis and Left Ventricular Hypertrophy, is actively recruiting participants, sponsored by eMyosound SAS.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without heart failure or cardiomyopathy. The main question it aims to answer is: • Can SWV be used to measure myocardial and liver stiffness in the study's target populations? Researchers will compare patients with ATTR-CM, patients without ATTR-CM, and a control group to determine the distributions of SWV in each population. Participants will: * Have a standard cardiology assessment, including a physical exam, blood work, and an echocardiogram. * Undergo an investigational assessment with the eMyosound LYRA device to measure SWV in their myocardium and liver. * Have the investigational assessment repeated by a second observer to assess measurement reliability.
Primary Outcome
These measurements include: Myocardial Acoustic Radiation Force (ARF)-SWV, defined as the velocity projected along the muscle fibers during diastasis. Myocardial Natural (N)-SWV, measured during both mitral valve closure (MVC) and aortic valve closure (AVC). Hepatic ARF-SWV, measured in two distinct regions of the right liver lobe.
Conditions Studied
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-07 |
What NCT07215715 shows while recruiting
NCT07215715 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 936-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (84% lower).
The record links to 5 conditions, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 0 interventions.
NCT07215715 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07215715 about?
NCT07215715 is a clinical study titled "US Benchmarking Clinical Study". The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without...
What is the current status of trial NCT07215715?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-09-16. Estimated completion is 2026-07.
What conditions does trial NCT07215715 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis, Left Ventricular Hypertrophy, HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Who is sponsoring clinical trial NCT07215715?
This trial is sponsored by eMyosound SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215715 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215715's enrollment target sits among peer trials
150 6th of 8 higher than 3 of 8 other Cardiac Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
RECRUITING · NA
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
-
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI